Spain's Almirall H1 net sales rise, reiterates 2026 guidance

Almirall

24/07/2026 06:10

    

    Overview
  
Spain-based dermatology drugmaker's H1 2026 net sales rose 7.5% year-over-year
EBITDA for H1 2026 grew 23.7%, driven by European dermatology business
Company reiterated full-year 2026 guidance and announced Certest Biotec research collaboration

    

    Outlook
  
Almirall reiterates 2026 net sales growth guidance of 9-12%
Company expects 2026 EBITDA between €270 mln and €290 mln
Almirall expects first R&D pipeline readouts towards end of 2026

    

    Result Drivers
  
EUROPEAN DERMATOLOGY GROWTH - European dermatology business net sales rose 18.1% YoY, supported by key products and favorable market conditions
BIOLOGICS PORTFOLIO - Ebglyss net sales grew 88.2% YoY and Ilumetri rose 10.5% YoY, driven by sustained growth in recent launch markets and strong market position
BROAD DERMATOLOGY PORTFOLIO - Wynzora and Klisyri delivered double-digit sales growth, contributing to overall portfolio performance

    
Company press release: ID:nBw15t7cba

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
H1 Sales
 
EUR 602.70 mln
 
H1 EBITDA
 
EUR 150.70 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Almirall SA is €14.13, about 27.8% above its July 23 closing price of €11.06
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 23 three months ago

    

    Reuters Recommended Reads
  
July 23 - Switzerland's Galderma H1 net sales rise, lifts FY guidance
July 23 - Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance 
July 21 - Celldex to stop skin disease study after trial setback

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)